Newer alternative treatments for sickle cell anemia include crizanlizumab (Adakveo) which is a monoclonal antibody therapy
This trend is associated with substantial increases in morbidity and mortality, driven by complications including type 2 diabetes (T2D), metabolic dysfunction-associated steatotic liver disease (MASLD), and cardiovascular disease
Fatigue is by far the main symptom, especially after minimal physical effort, but close behind are shortness of breath, headaches, tingling/numbness in the arms and legs, poor focus and concentration, ringing in ears, change in vision, loss of smell and taste, palpitations
The recommendation is to establish and optimize the cagrilintide-retatrutide combination first before considering any additional peptides